Trial · NCT04668209
Results by group362
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 362
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | Silmitasertib (CX-4945) in Combination With Standard of Care | Experienced Incidence of Treatment Emergent Adverse Events | 10 | Participants | |
| Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | Standard of Care | Experienced Incidence of Treatment Emergent Adverse Events | 7 | Participants | |
| Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | Silmitasertib (CX-4945) in Combination With Standard of Care | Did not experience Incidence of Treatment Emergent Adverse Events | 5 | Participants | |
| Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | Standard of Care | Did not experience Incidence of Treatment Emergent Adverse Events | 7 | Participants | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Silmitasertib | 3 | Standard Deviation 1.5 | Days | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Standard of Care | 3.4 | Standard Deviation 1.3 | Days | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Silmitasertib (CX-4945) in Combination With Standard of Care | 6 | Standard Deviation 4.1 | Days | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Standard of Care | 5.1 | Standard Deviation 2.9 | Days | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Silmitasertib (CX-4945) in Combination With Standard of Care | 7.3 | Standard Deviation 4.6 | Days | |
| To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm. | Standard of Care | 6 | Standard Deviation 3.3 | Days | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Silmitasertib (CX-4945) in Combination With Standard of Care | Day 14 | 13 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Standard of Care | Day 14 | 13 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Silmitasertib (CX-4945) in Combination With Standard of Care | Day 28 | 13 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Standard of Care | Day 28 | 13 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Silmitasertib (CX-4945) in Combination With Standard of Care | Day 14 / Death | 0 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Standard of Care | Day 14 / Death | 0 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Silmitasertib (CX-4945) in Combination With Standard of Care | Day 14 / Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) | 1 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Standard of Care | Day 14 / Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) | 2 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Silmitasertib (CX-4945) in Combination With Standard of Care | Day 14 / Hospitalized, on non-invasive ventilation or high flow oxygen devices | 1 | Participants | |
| To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28. | Standard of Care | Day 14 / Hospitalized, on non-invasive ventilation or high flow oxygen devices | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04668209/results